SEC Comment Letter for TALPHERA, INC. (TLPH) (CIK 0001427925) (TLPH) — Jun 12, 2017
TALPHERA, INC. (TLPH) (CIK 0001427925)
Date: June 12, 2017 · CIK: 0001427925 · Accession: 0000000000-17-020544
AI Filing Summary & Sentiment
Reasoning
Letter
June 12, 2017 Vincent Angotti Chief Executive Officer AcelRx Pharmaceuticals, Inc. 351 Galveston Drive Redwood City, CA 94063 AcelRx Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 5, 2017 File No. 333-218506Re: Dear Mr. Angotti: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Johnny Gharib at (202) 551-3170 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Robert W. Phillips, Esq.
Show Raw Text
June 12, 2017
Vincent Angotti
Chief Executive Officer
AcelRx Pharmaceuticals, Inc.
351 Galveston Drive
Redwood City, CA 94063
AcelRx Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 5, 2017
File No. 333-218506Re:
Dear Mr. Angotti:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Johnny Gharib at (202) 551-3170 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Robert W. Phillips, Esq.